Steris (STE) Q4 2026 Earnings Transcript

STERIS posted another record fiscal 2026, with 9% revenue growth, 10% adjusted EPS growth to $10.17, and free cash flow of $982.9 million, while segment milestones were reached across Healthcare, AST, and Life Sciences. Fiscal 2027 guidance calls for 7%-8% revenue growth, 9%-11% EPS growth to $11.10-$11.30, and about 50 bps of EBIT margin expansion, partly offset by about $60 million-$65 million of tariff spend and a 25% tax rate. The company also raised its quarterly dividend to $0.63 and authorized a new $1 billion buyback program, while noting near-term AST volatility from inventory management and weather disruptions.

Analysis

STERIS is turning a solid operating print into a self-funded capital returns story, but the more interesting point is that management is effectively telling us margin expansion is now more about mix and execution than macro relief. The company has already normalized much of the supply-chain damage from the prior cycle, so future upside is less about fixing broken procurement and more about harvesting higher-throughput consumables, service workflow software, and facility rationalization. That makes the stock less levered to broad med-tech capex and more levered to procedure growth plus attach-rate gains, which usually deserves a premium multiple relative to slower, more cyclical healthcare equipment names.

The near-term risk is that the market underestimates how long AST can stay choppy if customers keep trimming inventories and weather normalizes without a clean snapback in deferred procedures. Management’s own guidance implies the first half can be messy, so the easiest path to disappointment is if the expected H2 inflection slips by even one quarter; that would compress sentiment despite intact full-year numbers. Tariffs look more manageable than feared, but the real hidden drag is tax: a persistently higher effective rate can quietly cap EPS upside even if EBIT outperforms, which makes buybacks less powerful than they appear on headline cash flow.

The buyback authorization is the most underappreciated catalyst. Because the company is under-levered and can repurchase consistently without stressing the balance sheet, every quarter of execution should tighten the float and support the multiple, especially if the stock remains weak into the June cash deployment window. The contrarian view is that the market may be over-focusing on tariff noise and underpricing the multi-year margin lift from automation and consolidation in sterility assurance; if that project lands, STE can look like a steady mid-teens total-return compounder rather than just a defensive healthcare compounder.

Key Decisions for Investors

• Long STE on any post-earnings weakness over the next 1-3 weeks; target 12-month upside from buybacks + margin expansion with downside protected by recurring demand and strong FCF conversion.
• Pair trade: long STE / short a more capex-cyclical med-tech industrial name for 6-9 months; the thesis is STE’s recurring consumables/services mix should outperform if procedure growth stays mid-single digit but equipment budgets soften.
• Sell cash-secured puts on STE 1-2 quarters out at strikes ~5-8% below spot; collect premium while waiting for AST inventory normalization and first-half volatility to clear.
• If holding a healthcare basket, overweight STE versus lower-quality sterilization/consumables peers; the cleaner balance sheet and buyback cadence create a more reliable earnings floor.
• Set a catalyst watch for the next 2 quarters: if AST re-accelerates faster than guided, add on breakout; if not, fade rallies because the market is likely paying today for a recovery that may already be in the stock.